The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
Open accessAbstract
Current therapies for non-Hodgkin lymphoma commonly include CD20 mAb to deplete tumor cells. However, the response is not durable in a substantial proportion of patients. Herein, we report our studies in mice testing the hypothesis that heterogeneity in endogenous tissue CD20+ B cell depletion influences in vivo lymphoma therapy. Using highly effective CD20 mAbs that efficiently deplete endogenous mature B cells and homologous CD20+ primary lymphoma cells through monocyte- and antibody-dependent mechanisms, we found that lymphoma depletion and survival were reduced when endogenous host B cells were not depleted, particularly a rare IL-10-producing B cell subset (B10 cells) known to regulate inflammation and autoimmunity. Even small numbers of adoptively transferred B10 cells dramatically suppressed CD20 mAb-mediated lymphoma depletion by inhibiting mAb-mediated monocyte activation and effector function through IL-10-dependent mechanisms. However, the activation of innate effector cells using a TLR3 agonist that did not activate B10 cells overcame the negative regulatory effects of endogenous B10 cells and enhanced lymphoma depletion during CD20 immunotherapy in vivo. Thus, we conclude that endogenous B10 cells are potent negative regulators of innate immunity, with even small numbers of residual B10 cells able to inhibit lymphoma depletion by CD20 mAbs. Consequently, B10 cell removal could provide a way to optimize CD20 mAb-mediated clearance of malignant B cells in patients with non-Hodgkin lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 2×
“Since monocytes express the IL-10 receptor at high levels (19), the effect of adoptively transferred B10 cells on monocyte activation was examined in vivo.”
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835 · cited 2×
“Other than for Fc receptor polymorphisms in some patients (8, 9), molecular explanations for variable responses remain unknown (4), but are undoubtedly due to inconsistency in the strength of effector mechanisms among patients and molecular variability among tumors.”
Yanaba, K., Bouaziz, J.-D., Matsushita, T., Tsubata, T., & Tedder, T. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900270 · Cited by 503
Self-citationHeikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449 · cited 2×
“Furthermore, repeated CpG administration has negative consequences in mice, including severely altered morphology and functionality of lymphoid organs, multifocal liver necrosis, and hemorrhagic ascites (59).”
Matsushita, T., Horikawa, M., Iwata, Y., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001307 · Cited by 394
Self-citationIntrinsic Requirement for Zinc Finger Transcription Factor Gfi-1 in Neutrophil Differentiation
Hock, H., Hamblen, M. J., Rooke, H. M., Traver, D., Bronson, R. T., Cameron, S., & Orkin, S. H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00501-0 · Cited by 384 · cited 1×
“Gfi1–/– mice lack phenotypically mature neutrophils, while morphologically normal monocytes are present in normal numbers (33).”
Species-specific Regulation of Toll-like Receptor 3 Genes in Men and Mice
Heinz, S., Haehnel, V., Karaghiosoff, M., Schwarzfischer, L., Müller, M., Krause, S. W., & Rehli, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301476200 · Cited by 202
Thompson, K. A., Strayer, D. R., Salvato, P. D., Thompson, C. E., Klimas, N., Molavi, A., Hamill, A. K., Zheng, Z., Ventura, D., & Carter, W. A. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01709367 · Cited by 92
Cited by
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions
Yoshizaki, A., Miyagaki, T., DiLillo, D. J., Matsushita, T., Horikawa, M., Kountikov, E. I., Spolski, R., Poe, J. C., Leonard, W. J., & Tedder, T. F. (2012) · Nature · doi:10.1038/nature11501 · Cited by 634
Self-citationB cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production
Rosser, E. C., Oleinika, K., Tonon, S., Doyle, R., Bosma, A., Carter, N. A., Harris, K. A., Jones, S. A., Klein, N., & Mauri, C. (2014) · Nature Medicine · doi:10.1038/nm.3680 · Cited by 451
Human regulatory B cells in health and disease: therapeutic potential
Mauri, C., & Menon, M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci85113 · Cited by 418
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
PD-L1hi B cells are critical regulators of humoral immunity
Khan, A. R., Hams, E., Floudas, A., Sparwasser, T., Weaver, C. T., & Fallon, P. G. (2015) · Nature Communications · doi:10.1038/ncomms6997 · Cited by 387
IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia
Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., & Bar-Sagi, D. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0843 · Cited by 357
Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation
Guo, S., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25720 · Cited by 315
B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E., Steinhoff, M., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 304
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
B10 Cells: A Functionally Defined Regulatory B Cell Subset
Tedder, T. F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401329 · Cited by 283
Self-citationComplement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity
Lu, Y., Zhao, Q., Liao, J.-Y., Song, E., Xia, Q., Pan, J., Li, Y., Li, J., Zhou, B., Ye, Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.015 · Cited by 280
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 275
Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway
Shao, Y., Lo, C. M., Ling, C. C., Liu, X. B., Ng, K. T.-P., Chu, A. C. Y., Ma, Y. Y., Li, C. X., Fan, S. T., & Man, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.026 · Cited by 158
Maseda, D., Candando, K. M., Smith, S. H., Kalampokis, I., Weaver, C. T., Plevy, S. E., Poe, J. C., & Tedder, T. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300649 · Cited by 144
“Human and mouse B10 cell IL-10 production is central to their ability to negatively regulate innate and Ag-specific adaptive immune responses as well as inflammation and autoimmune disease (23-25, 28-33).”
BackgroundSelf-citationAsare, P. F., Roscioli, E., Hurtado, P. R., Tran, H. B., Mah, C. Y., & Hodge, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01298 · Cited by 50
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
Potential importance of B cells in aging and aging-associated neurodegenerative diseases
Biragyn, A., Aliseychik, M., & Rogaev, E. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0615-8 · Cited by 25
Metadata
- Authors
- Horikawa, M., Minard-Colin, V., Matsushita, T., & Tedder, T. F.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-11-01
- Volume
- 121
- Issue
- 11
- Pages
- 4268-4280
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2068367973
- Cited by
- 191
- References
- 9
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.